HIV Prevention by Oral Preexposure Prophylaxis by Heneine, W. & Kashuba, A.
HIV Prevention by Oral Preexposure Prophylaxis
Walid Heneine1 and Angela Kashuba2
1Laboratory Branch, Division of HIV/AIDS Prevention, National Center for HIV, Hepatitis, STD,
and Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333
2Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, and UNC
Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599
Correspondence: wheneine@cdc.gov; akashuba@unc.edu
The impressive advances in antiretroviral (ARV) therapyof chronic human immunodeficiency
virus (HIV) infections during the last decade and the availability of potent ARV drugs have
fueled interest in using chemoprophylaxis as a novel HIV prevention strategy. Preexposure
prophylaxis (PrEP) refers to the use of ARV drugs in HIV-negative persons to prevent HIV
infection. The rationale for PrEP builds on the success of ARV prophylaxis in preventing
mother-to-child transmission of HIVand on a large body of animal studies that show the effi-
cacy of PrEP against mucosal and parenteral infection. We focus on oral administration of
ARV drugs for prevention of HIV infection. Identifying an effective prophylactic pill that
individuals can take outside the setting of sexual intercourse precludes the necessity to
disclose such use to their partners, thereby empowering those who might not be in a position
to negotiate with their partners. Several human clinical trials evaluating the efficacy of daily
regimens of the HIV reverse-transcriptase (RT) inhibitors tenofovir disoproxil fumarate (TDF)
or Truvada (TDF and emtricitabine [FTC]) are under way among high-risk populations. The
results of one trial among men who have sex with men showed that daily Truvada was safe
and effective, providing the first support for oral PrEP as a prevention strategy. Here we
outline the preclinical and clinical research on oral PrEP, pharmacologic considerations,
and future directions and challenges.
The prevention of human immunodeficiencyvirus (HIV) infection remains a critical pub-
lic health priority. It is estimated that 2.7 million
new HIV infections have occurred worldwide in
2008 at a rate that continues to outpace the rate
at which HIV-infected persons enter treatment
(UNAIDS 2009). While work on HIV vaccine
discovery continues to progress, prevention
research has focused in recent years on a variety
of new biomedical strategies for preventing
infection, such as male circumcision, topical
gels containing antiretroviral (ARV) drugs, or
preexposure prophylaxis (PrEP) by oral ARV
drugs (Padian et al. 2008). PrEP entails provid-
ing HIV-negative individuals with oral ARV
drugs to prevent HIV acquisition. Since 1995,
the continually impressive advances in ARV
therapy of HIV-infected individuals and the
availability of potent ARV drugs with known
safety and potency profiles have fueled interest
in using ARV drugs for HIV prevention. The
rationale for PrEP is further supported by the
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fact that ARV drugs provided to pregnant
women with HIV infection were shown to dra-
matically reduce the risk of perinatal transmis-
sion and protect treated breastfed infants of
HIV-infected mothers (Hu 2000). Mathemati-
cal models estimate that over the next 10 years,
an effective PrEP program could prevent 2.7–
3.2 million new HIV-1 infections in sub-
Saharan Africa (Li 2009). This potentially sig-
nificant public health benefit requires very
high PrEP efficacy, which might be lost or
substantially reduced with a PrEP efficacy of
,50%. Therefore, identifying highly effective
PrEP modalities is critical. In this work we
provide an overview of oral PrEP for HIV
prevention, discuss ARV drug selection and
pharmacology, animal studies, current clinical
trials, and implementation planning.
EARLY EVENTS IN HIV TRANSMISSION
AND IMPLICATIONS FOR PrEP
The current understanding of mucosal HIV
transmission suggests that HIV first replicates
at a low level at the mucosal point of entry in
the new host. PrEP can be designed to exploit
this brief period of virus vulnerability and
block HIV from establishing itself as a persis-
tent infection. Early infection events have been
largely derived from monkey model studies of
vaginal infection with the simian immunodefi-
ciency virus (SIV) (Haase 2005). These studies
have consistently shown that, after penetration
of SIV into the cervicovaginal epithelium, infec-
tion in cervicovaginal tissues during the first
1–3 d is limited to extremely small numbers
of productively infected cells in rare foci (Hu
et al. 2000; Miller et al. 2005; Li et al. 2009).
This small local founder population of infected
cells expands in the following days, possibly by
accretion of new infections around the initial
clusters (Li et al. 2009). Continuous expansion
at the point of entry and dissemination of
both virus and infected cells through lympha-
tic drainage and the bloodstream establishes a
sustainable infection in secondary lymphoid
organs (Miller et al. 2005). In ,2 wk, a very
small founder population of productively
infected cells at the portal of entry progresses
to systemic infection with a burst of virus pro-
duction and depletion of gut CD4þ T cells. At
this point, a robust virus-specific immune
response can contain viral replication only to
a certain degree (Reynolds et al. 2005). Thus,
the first days of infection at the mucosa when
replication is limited to small clusters of in-
fected cells are the periods of maximum virus
vulnerability and represent a window of op-
portunity for intervention. Mucosal HIV infec-
tion can be conceivably prevented by a rapid
and efficient host immune response or by limit-
ing the size of founder populations of infected
cells to a theoretical threshold under which
infection cannot be established. HIV vaccines
have so far been unable to elicit highly pro-
tective immune responses. Anti-inflammatory
agents that interfere with innate host responses
and limit expansion of founder populations
have shown promising results in macaques,
although the existence of occult infections is still
a possibility (Li et al. 2009). However, by inhib-
iting key steps in HIV replication such as entry
or reverse transcription, ARV drugs delivered
by oral PrEP may conceivably block the estab-
lishment of founder populations of infected
cells, or prevent their expansion leading to a
dead-end infection. As described below, data
from animal models and also from a recent
human trial support the promise of this preven-
tion strategy.
ARV DRUGS FOR ORAL PrEP
Beyond mechanical barriers, there are only two
biological strategies to prevent HIV infection at
the moment of exposure: modification of a host
defense (such as a vaccine stimulating neutraliz-
ing antibodies) and/or the use of ARV therapy
to saturate the cells receptive to HIV infection
and replication. The significance of finding a
drug, or drug combination, that people can
control and use intermittently to protect them
against HIV acquisition is immense. In order
to choose an effective ARV regimen for PrEP,
investigators must choose the right drugs,
which target the right sites of infection in
the right concentration for the right amount
of time.
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Drug candidates for oral PrEP have largely been
selected from currently approved drugs for treat-
ment of individuals infected with HIV-1 because
development of drugs exclusively for HIV pre-
vention has been limited. There are currently
.30 drugs or drug combinations that have been
approved for treatment of HIV (Department of
Health and Human Services Panel on Antiretro-
viral Guidelines for Adults and Adolescents Jan-
uary 10, 2011), and a number of desirable drug
characteristics for PrEP overlap with those for
treatment: good tolerability, low pill burden,
infrequent dosing, and resistance profiles with
minimal cross resistance. Preintegration drugs
(chemokine receptor antagonists, nucleoside
and nonnucleoside analog reverse-transcriptase
inhibitors, and integrase inhibitors) are currently
thought to be more suitable than postintegration
drugs (protease inhibitors, maturation inhibi-
tors) for prevention, although direct evidence
to support this assumption is lacking.
One pharmacokinetic property considered
important for PrEP drugs targeting sexual
transmission includes the ability to rapidly reach
and accumulate in genital and rectal tissues.
Antiretrovirals differ greatly in their ability to
penetrate mucosal tissues or secretions (Cohen
et al. 2007; Dumond et al. 2007, 2009; Jones
et al. 2009; Brown et al. 2011). In general, highly
protein-bound compounds do not gain access
to these secondary compartments because of
their affinity for plasma proteins such as albu-
min and a1-acid glycoprotein. Drugs such as
the protease inhibitors, which are 95%–99%
bound to plasma proteins, generally achieve
female genital tract concentrations ,50% those
in the plasma (Nicol and Kashuba 2010). In
contrast, most nucleoside-analog reverse-tran-
scriptase inhibitors (NRTIs) have a low degree
of protein binding (,0.7%–49%) and achieve
concentrations two- to sixfold higher in mu-
cosal tissue than in plasma.
However, plasma protein binding is not the
only predictor of ARV exposure. For example,
maraviroc, a cellular entry inhibitor that shows
75% protein binding in blood plasma, has high
penetration into cervicovaginal fluid (CVF) and
vaginal tissue. After 7 d of dosing at 300 mg
of maraviroc twice daily, the areas under the
concentration–time curve (AUCs) in CVF and
vaginal tissue are 2.7 and 1.9 times higher,
respectively, than blood plasma (Dumond et al.
2009). Raltegravir, an integrase inhibitor that
is 83% protein bound in plasma, has also been
shown to penetrate well in the female genital
tract: The concentrations of the drug in CVF
after multiple dosing are up to twofold higher
than those in plasma (Jones et al. 2009). Figure 1
summarizes all available data of antiretroviral
penetration into cervicovaginal fluid, cervical
and vaginal tissues, and rectal tissues.
One additional factor relating ARV phar-
macokinetics to efficacy at mucosal surfaces is
protein binding within the mucosal secretions
themselves. The concentrations of albumin and
a1-acid glycoprotein in cervicovaginal fluid
are ,1% of the values in plasma (Salas Herrera
et al. 1991). Although the protein binding of
drugs in genital secretions has not been exten-
sively evaluated, maraviroc has recently been
shown to have 10-fold less protein binding in
CVF than in plasma (7.5% vs. 75%) (Dumond
et al. 2009). This phenomenon must be con-
sidered in pharmacokinetic–pharmacodynamic
analysis of ARV prevention strategies, as the free
drug concentration represents the fraction of
drug available to be active against HIV infection.
Therefore, even though total drug concentration
maybe lowerthanbloodplasmainmucosalsecre-
tions, the free drug concentration may be similar
to, or higher than, these plasma concentrations.
The extent of penetration of drugs into rectal
tissues also has implications for HIV trans-
mission. Data in these tissues are sparse, but are
available for some nucleoside-analog reverse-
transcriptase inhibitors (NRTI), nonnucleoside-
analog reverse-transcriptase inhibitors (NNRTI),
protease inhibitors (PI), and entry inhibitors.
Taken orally, tenofovir and emtricitabine con-
centrate in rectal tissues, achieving concentra-
tions 33- and fourfold greater than plasma.
Exposures (AUC12 h) of maraviroc are 30
times higher in rectal tissues than in plasma
(Brown et al. 2011). Darunavir, etravirine,
and ritonavir have exposures three-, seven-,
and 13-fold higher than plasma.
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The nucleoside/tide analogs require cellular
uptake and phosphorylation to be active against
the RT enzyme. Intracellular concentrations
of tenofovir diphosphate and emtricitabine
triphosphate have been recently evaluated in
cervical, vaginal, and rectal tissues after a single
dose (Patterson et al. 2010). The accumulation
of tenofovir diphosphate and emtricitabine
triphosphate was wide-ranging depending on
tissue type. In rectal tissue, the exposure of
tenofovir diphosphate was 100-fold higher
than in vaginal or cervical tissue. Yet in vaginal
and cervical tissue, the exposure of FTC was
10-fold higher than in rectal tissue. In all tissues,
emtricitabine triphosphate was not detectable
beyond 2 d postdose. These results provide
one plausible pharmacologic explanation for
the recent disappointing results from the FEM-
PrEP trial with Truvada (Matassa 2011) (see
below). This study was stopped prematurely
for futility. FEM PrEP used the same daily
dosing of Truvada, which showed 44% efficacy
in preventing HIV transmission in men who
have sex with men, but enrolled only high-risk
women. These results show the need for a bet-
ter understanding between ARV exposure in
mucosal tissues and protection from HIV
infection.
The Right Site
Over the past few years the HIV transmission
event has become increasingly well understood
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Figure 1. Penetration of oral antiretrovirals into mucosal surfaces. Blood plasma AUC ratios of tissue or mucosal
secretions under steady-state conditions relative to blood plasma are reported unless otherwise marked. The
dotted line represents drug concentrations in tissue or secretions equivalent to blood plasma. Drugs falling
above the line concentrate at mucosal surfaces. Drugs falling below the line achieve concentrations at mucosal
surfaces lower than blood plasma. The number in parentheses represents the ratio of mucosal surface AUC to
blood plasma AUC. NRTI, nucleoside-analog reverse-transcriptase inhibitors; NNRTI, nonnucleoside-analog
reverse-transcriptase inhibitors; PI, protease inhibitors; EI, entry inhibitors; II, integrase inhibitors TFV (teno-
fovir); FTC (emtricitabine); 3TC (lamivudine); ZDV (zidovudine); ddI (didanosine); ABC (abacavir); d4T (sta-
vudine); ETR (etravirine); NVP (nevirapine); DLV (delavirdine); EFV (efavirenz); IDV (indinavir); RTV
(ritonavir); DRV (darunavir); APV (amprenavir); LPV (lopinavir); ATV (atazanavir); SQV (saquinavir);
MRV (maraviroc); RAL (raltegravir).
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Derdeyn 2009). This information is critical for
designing effective strategies for HIV preven-
tion. The most current evidence suggests the
initial target of the transmitted/founder virus
at mucosal sites is a CD4þ T cell expressing
high levels of CCR5 and a4b7 receptors (Chun
et al. 1998). A strategy targeting these cells
within vulnerable mucosal tissues (vaginal, cer-
vical, and colorectal) may assist in selecting cer-
tain drugs for HIV prevention strategies. For
example, orally administered drugs that reach
these tissues in high concentrations for an
extended period of time and target these spe-
cific cells would be preferentially selected for
further development.
The Right Concentration
The target drug exposure required for prevent-
ing HIV infection at human mucosal surfaces
is unknown. Therefore, the working assump-
tion is that higher drug exposures are better at
conferring protection. Although human trials
will ultimately determine whether tissue con-
centrations achieved with oral drug dosing can
prevent HIV transmission, preclinical research
(animal studies and human tissue culture ex-
periments) can provide valuable information
and can guide the next steps in the research
and practice of PrEP. These models can evaluate
potential cell populations/subpopulations that
are not adequately protected by current PrEP
regimens, can help to define better drug regi-
mens that include other drug classes such as
entry inhibitors, and can evaluate the effect of
drug-resistant viruses on protective efficacy
(Veazey et al. 2005).
Performing early dose-ranging tissue con-
centration studies in phase I pharmacokinetic
investigations, coupled with a preclinical under-
standing of concentration targets required to
prevent HIV infection, allows for an optimal
selection of drugs, doses, and dosing frequency
to be implemented in later stage clinical trials.
These studies should evaluate not only drug
penetration in rectal and vaginal tissues, but
also the degree of drug exposure in cells that
are primary targets during early mucosal infec-
tion such as activated/resting T cells, dendritic
cells, or Langerhans cells. As an example, the
threshold for concentrations of TFV-DP and
FTC-TP that results in tissue protection has
not been absolutely defined in macaques or
tissue explants. These data, coupled with the
knowledge of how drugs behave in tissues with
certain dosing strategies, can be used to deter-
mine the minimal dose and dose frequency
required for protection, which can then be
used to optimize phases II and III clinical trial
design.
One such dose-ranging tissue concentration
study currently ongoing is HPTN 066 within
the HIV Prevention Trials Network: This multi-
site phase I study is scheduled to be completed
in 2011. It involves four different treatment reg-
imens in HIV-negative men and women (arm 1:
300 mg TDF/200 mg FTC weekly; arm 2:
300 mg TDF/200 mg FTC twice weekly; arm
3: 600 mg TDF/400 mg FTC twice weekly;
and arm 4: 300 mg TDF/200 mg FTC daily).
Sampling of rectal, seminal, and vaginal fluids,
plasma, cells, and tissues will be performed to
assess the dose proportionality of intracellular
phosphorylated metabolites of TFV and FTC
and to quantify their intraindividual variability.
The information from this study will fill a large
gap in the knowledge of intracellular kinetics of
these medications at multiple mucosal surfaces
and will help identify the time periods during
which specific dosing strategies confer protec-
tion, once target concentrations are identified
(using in vitro, animal, or clinical study data).
Quantification of the intra-individual variabil-
ity will enable future studies to use drug con-
centrations as a determinant of adherence to
medication regimens—a critical component to
interpret the findings of HIV prevention stud-
ies, which remains suboptimal.
The Right Amount of Time
Infection of HIV in mucosal tissues occurs
quickly. These data are reviewed in detail in
Shaw and Hunter (2011). Knowing that an ini-
tial round of HIV replication can occur in
mucosal tissue within 24 h of exposure suggests
that antiretroviral drugs need to be at the site
of infection before, or very shortly after, HIV
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exposure. Additionally, data demonstrating re-
coverable infectious virus up to 8 d after ino-
culation of cervical tissue cultures suggest that
significant drug exposure may need to be avail-
able for days after exposure (Collins et al. 2000).
Particular emphasis is being placed on longer-
acting drug formulations for next-generation
PrEP agents (vaginal rings, intramuscular depot
injections), which will require less frequent dos-
ing and could be taken independently of virus
exposure.
PRECLINICAL RESEARCH IN ANIMAL
MODELS
The potential use of antiretroviral drugs for
HIV prophylaxis has been studied extensively
in nonhuman primate models of mucosal and
parenteral SIV or SHIV (SIV/HIV chimera)
transmission and, more recently, in humanized
mouse models (Table 1). Early work with sub-
cutaneous TFV in macaques showed the first
proof-of-concept data on the efficacy of ARV
prophylaxis against intravenous virus inocula-
tion (Tsai et al. 1995). Subsequent work showed
that postexposure prophylaxis with TFV can
protect against intravenous SIV inoculation
and helped define the optimal timing for ini-
tiating ARV therapy and the need for a 4 wk
treatment to achieve protection (Tsai et al.
1998). Indications that ARV drugs administered
before exposure could also prevent oral SIV
infection came from studies that used different
doses of TFV (Van Rompay et al. 1998, 2006).
More recently, repeat low-dose macaque models
of mucosal transmission have been developed
and used to assess PrEP efficacy of different
ARV regimens and modalities (Otten et al.
2005; Subbarao et al. 2006). These models
closely mimic human transmission of HIV in
many aspects, including the use of a lower and
more physiologic virus inoculum than that
used in conventional single high-dose challenge
models. In addition, the SHIV challenge con-
tains an R5-tropic HIV-1SF162 envelope similar
to naturally transmitted viruses. Virus exposures
are repeated to mimic high-risk human expo-
sures, thereby providing the opportunity to meas-
ure protection against multiple transmission
events in each animal (Subbarao et al. 2006;
Garcia-Lerma et al. 2008; Keele and Derdeyn
2009). Using such a model of rectal infection
to assess the efficacy of TDF, FTC, or TDF/
FTC combination at human equivalent dosing,
it was found that daily TDF provided little pro-
tection, whereas FTC reduced risk by 3.8-fold
(Subbarao et al. 2006, Garcia-Lerma et al.
2008, 2010). In contrast, TDF/FTC combina-
tion was more protective and provided a nearly
eightfold lower risk of infection; a higher
FTC/TFV dose afforded full protection (Gar-
cia-Lerma et al. 2008). These experiments
showed a dose-response relationship and sug-
gested that TDF/FTC may be more effective
than either TDF or FTC alone against rectal
infection. Data on PrEP efficacy against vaginal
challenges in macaques are not available. These
studies are important because similar to what is
observed in humans, oral Truvada in macaques
achieves different drug exposures in vaginal tis-
sues than in rectal tissues. However, data from a
humanized mouse model showed that a high
dose of TDF/FTC combination administered
intraperitoneally protected mice against a vagi-
nal HIV infection (Denton et al. 2008). Recent
findings also showed that oral PrEP with either
raltegravir or maraviroc protected humanized
mice from vaginal HIV infection (Neff et al.
2011), although drug concentrations were not
measured.
Several important observations of potential
relevance to humans have been made from the
analysis of PrEP breakthrough infections in
macaques. First, drug resistance can emerge if
ARV therapy continues after PrEP fails. In one
macaque study, two of six animals infected dur-
ing daily PrEP with FTC or Truvada showed
selection for drug-resistant viruses (Garcia-
Lerma et al. 2008). In both macaques, the
M184V mutation associated with FTC resis-
tance was selected, thus reiterating the impor-
tance of closely monitoring PrEP failures to
minimize drug-resistance emergence. Second,
PrEP breakthroughs during FTC and Truvada
treatment had lower acute viremias than control
animals. A reduction in viremia during PrEP
might conceivably contribute to a decrease in
HIV-1 transmissibility at the population level
W. Heneine and A. Kashuba



















Table 1. Efficacy of preexposure prophylaxis modalities in animal models of mucosal and intravenous infection




dose Interventions Main findings
Tsai et al. 1995 Long-tailed
macaques





TFV initiated 48 h before exposure






TFV, 30 mg/kg Subcutaneous Oral, SIVmac251
(105 TCID50)













TDF initiated 1 d before exposure
and maintained during
continuous virus inoculations;
one additional dose after the last
virus exposure










Repeated cycles of daily TDF
initiated 1–2 d before exposure
Partial prophylactic efficacy;











Daily or weekly TDF All controls animals infected
after 1.5 exposures; 3 of 4
TDF-treated animals



















daily or intermittent FTC/TFV
(subcutaneous)
Risk of infection reduced with
human equivalent doses of
FTC (fourfold) and Truvada
(eightfold); no infection
with FTC and high TFV



































































Daily FTC/TDF initiated 48 h before

















High to moderate efficacy with
2 weekly human equivalent
doses of Truvada given at
different intervals


























































and could add to the overall effectiveness of
PrEP. Attenuated acute viremia might also re-
duce early CD4þ T cell depletion, help to pre-
serve immune function, and attenuate the
course of HIV infection (Mehandru et al. 2004).
Animal models have also been used to
explore the efficacy of intermittent drug dosing
with TFV or Truvada. Intermittent PrEP can
reduce the risks of drug toxicities, increase ad-
herence, minimize drug-resistance emergence,
and be more cost effective. Both FTC-TP and
TFV-DP have long (40 to .100 h) intracellular
half-lives in humans and can potentially achieve
extended prophylactic activity when adminis-
tered intermittently (Wang et al. 2004; Hawkins
et al. 2005; Pruvost et al. 2005). Intermittent
PrEP regimens of TDF or Truvada can be
designed to be exposure driven or to follow a
fixed schedule. Studies in macaques showing
protection from oral or rectal SIV/SHIV expo-
sures by a two-dose subcutaneous regimen
containing TFV or TFV/FTC have provided
the first proof-of-concept evidence for inter-
mittent PrEP (Van Rompay et al. 1998; Garcia-
Lerma et al. 2008). However, the high drug
doses and subcutaneous drug delivery might
have overestimated efficacy in both studies.
More recent work using human equivalent
doses of Truvada showed that macaques can
be protected from rectal SHIV infection by sev-
eral PrEP modalities, including a single oral
dose given 1–7 d before exposure, followed by
a second dose 2 h after exposure (Garcia-Lerma
et al. 2010). Exposure-driven prophylactic
modalities initiated around the time of expo-
sure also maintained protection. These studies
showed that intermittent PrEP, particularly
with long-acting ARV drugs, can be highly
effective and have a wide window of protec-
tion. They strengthen the possibility of develop-
ing feasible, cost-effective strategies to prevent
HIV transmission in humans.
HUMAN CLINICAL TRIALS
A number of challenges currently exist for
human HIV prevention trials. Unlike antire-
troviral treatment efficacy (with HIV RNA con-
centrations and CD4þ T cell counts), there is
currently no surrogate marker to use in place
of new HIV infections. Therefore, prevention
trials must enroll thousands of participants, fol-
lowed for several years, at significant expense,
in order to document efficacy. Additionally,
the regulatory environment for demonstrating
safe and effective marketable prevention strat-
egies is not well defined.
However, a number of clinical studies have
been initiated in multiple at-risk populations
with standard dosing of TDF with or without
FTC. As of February 2011, nine oral PrEP trials
enrolling .22,000 participants are at varying
stages of completion (Table 2). The at-risk
populations in these studies are heterosexual
men and women, men who have sex with men
(MSM), and intravenous drug users (IDUs).
All trials are using TDF-containing products,
either alone or in combination with FTC, and
all are evaluating daily use with the exception
of one pilot study of intermittent PrEP.
The first phase II safety study of daily TDF
among 936 high-risk women in Ghana, Nigeria,
and Cameroon for up to 12 mo saw no differen-
ces in adverse events or grade-3 or -4 laboratory
abnormalities between placebo and TDF users
(Peterson al. 2007).
The second clinical study to be published
evaluated daily use of the fixed-dose com-
bination of TDF þ emtricitabine (Truvada) in
men who have sex with men. A total of 2499
gay and bisexual men, other MSM, and trans-
gender women at high risk of HIV infection
participated in the six-country, four-conti-
nent preexposure prophylaxis initiative (iPrEx
study). In this study, daily use of Truvada
reduced HIV acquisition by 44% (Grant et al.
2010). Based on drug concentrations in plasma
and cryopreserved peripheral blood mononu-
clear cell cultures (PBMCs), a substantial num-
ber of subjects only appeared to be taking their
drug sporadically. In those subjects who were
90% adherent by pill counts, drug exposure,
and self-report, Truvada conferred 68% protec-
tion against HIV acquisition (Celum 2011).
Truvada was safe and generally well tolerated,
with higher rates of nausea and weight loss dur-
ing the first 4 wk of treatment compared with
placebo. The overall rate of side effects was
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very similar in both the FTC-TDF and placebo
groups, and severe side effects were rare.
Most recently, however, a trial in women
using daily dosing of Truvada (FEM-PrEP)
was halted for futility: It was determined that
substantial HIV prevention (i.e., .30%) could
not be attained with daily use of Truvada (Mat-
assa 2011; Roehr 2011). As of May 2011, the
study is undergoing orderly closure, and sample
and data analysis will determine whether this
result was because of a biological process (e.g.,
increased genital tract inflammation in this
population), adherence, or differential drug
exposure in genital tract tissues (as discussed
above).
In contrast to FEM-PrEP, interim results
from two studies, the Partners PrEP trial and
TDF2 (CDC 4940), have demonstrated clear effi-
cacy in reducing HIVacquisition. In the Partners
PrEP, both daily TDF and FTC/TDF reduced HIV
risk by 62% and 73%, respectively, in both men
and women, and the effects in women and men
were statistically similar (Baeten 2011). The study
is continuing with two active arms only to gather
additional comparative information. Likewise,
results of the TDF2 trial among heterosexual
Table 2. Summary of clinical trials investigating oral antiretrovirals for HIV prevention and expected dates of
results publication
2010 2011 2012 þ
iPrEx
Phase III trial of once-daily
oral TDF/FTC (Brazil,
Ecuador, Peru, South Africa,
Thailand, United States)
Showed that once-daily TDF/
FTC reduced risk of HIV
infection in gay men,
transgender women, and other
men who have sex with men an
average of 43.8%.
FEM-PrEP
Phase III trial of a once-daily dose
of TDF/FTC (Kenya, South Africa,
Tanzania)
Study’s data review committee
determined that the trial would not
be able to answer the question of
whether the study drug decreased
risk of HIV infection among
HIV-negative women at risk via
sexual transmission. The study will
be discontinued.
Partners PrEP
Phase III trial of once-daily oral
TDF and once-daily oral TDF/
FTC (Kenya, Uganda)
CDC 4323
Phase II trial of once-daily oral
TDF (United States)
The trial reported no serious
adverse events and preliminary
data show PrEP use did not
have a significant effect on HIV
risk behavior. Additional data
expected in 2011.
CDC 4940 (TDF2)
Phase II trial of once-daily
TDF/FTC (Botswana)
VOICE (MTN-003)
Phase IIb trial of once-daily oral
TDF, once-daily oral TDF/FTC,
and 1% tenofovir gel (South
Africa, Uganda, Zimbabwe). This
study has fully enrolled.
IAVI E001 and E002 in Kenya
and Uganda
This study is evaluating the safety
and acceptability of
intermittent and daily PrEP
regimens using TDF/FTC.
This study has completed.
CDC 4370





interventions alone and combined
with daily TDF/FTC
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participants in Botswana showed that daily
FTC/TDF provided an overall protective efficacy
of 62.6% (Thigpen 2011). Limiting analysis to
participants on study medication when in-
fected, the protective efficacy was 77.9%.
Looking beyond tenofovir and emtricita-
bine, next-generation PrEP drugs are being
evaluated, including maraviroc (a CCR5 recep-
tor antagonist) and TMC278 (a long-acting
NNRTI).
Finally, intermittent PrEP is being consid-
ered as an attractive strategy. Daily dosing may
not be practical for individuals who are only
occasionally exposed to high-risk encounters,
which can subsequently result in decreased rates
of adherence to medication regimens (pro-
phylaxis fatigue) and unnecessary systemic tox-
icity. A preliminary clinical study in Kenya and
Uganda is currently under way among 150 sero-
discordant couples to evaluate the safety and
acceptability of iPrEP (http://www.iavi.org).
In this investigation, subjects will take standard
doses of oral TDF/FTC once daily or intermit-
tently (defined as twice weekly plus coitus-
related dosing). Samples for blood plasma and
intracellular concentrations will be obtained.
FUTURE DIRECTIONS AND CHALLENGES
Based on the results of iPrEX, the Centers for
Disease Control and Prevention has issued
interim guidance for PrEP use among MSMs
and has begun with other U.S. Public Health
Service (PHS) agencies to develop PHS guide-
lines on the use of PrEP for MSM at high risk
for HIV infection (Centers for Disease Control
2011). However, until the safety and efficacy of
PrEP is determined in trials now under way
with populations at high risk for HIVacquisition
by other routes of transmission, PrEP should
be considered only for MSM. The iPrEX trial
results that showed a substantially higher efficacy
(68%) among adherent participants with de-
tectable ARV drugs provide strong evidence
that support for adherence to the ARV regimen
must be a routine component of any PrEP pro-
gram. To minimize the risk for drug resistance,
PrEP should not be started in persons with signs
or symptoms of acute viral infection unless
HIV-uninfected status is confirmed. Despite
the indications of biologic effectiveness, the
implementation of PrEP will need to overcome
many challenges to provide a meaningful benefit
at the population level. Mathematical models
have suggested that the effectiveness of PrEP
may be offset by low uptake, suboptimal adher-
ence, and risk compensation, which refers to
increases in HIVrisk behavior among PrEP users
on the assumption that they are protected
against HIV infection (Abbas et al. 2007; Desai
et al. 2008; Paltiel et al. 2009). As was the case
during the implementation of ARV for treating
HIV infections, plans for PrEP implementation
will likely include multiple components on opti-
mal drug delivery, safety screening, behavioral
intervention, integration of PrEP as part of com-
prehensive care, and monitoring the impact of
PrEP at the population level (Underhill et al.
2011). The promise of PrEP also raises impor-
tant research questions. These range from the
development and evaluation of next-generation
PrEP agents and modalities including episodic
dosing, new drug classes and combinations,
and long-acting formulations, to the assessment
of risks of PrEP-induced drug resistance (Super-
vie et al. 2010).
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